products

Azilsartan kaMedoxoMil CAS 863031-24-7 C30H23N4O8·K Pharmaceutical Grade Chemicals

Basic Information
Place of Origin: CHINA
Brand Name: MOSINTER
Certification: COA
Model Number: Circulatory System Drugs API - 12
Minimum Order Quantity: 1KG
Price: Negotiation
Packaging Details: Aluminum foil bag , kraft paper bag
Delivery Time: Within 7 days
Payment Terms: L/C, T/T
Supply Ability: Can be customized according to customer requirements
Detail Information
Name: Azilsartan KaMedoxoMil CAS: 863031-24-7
Form: Powder Molecular Formula: C30H23N4O8·K
Molecular Weight: 606.63 EINECS No: 1308068-626-2
High Light:

chemical raw materials

,

pharmaceutical raw materials


Product Description

Azilsartan kaMedoxoMil CAS 863031-24-7 C30H23N4O8·K Pharmaceutical Grade Chemicals
 

Description:

 

Azisartan ester potassium is a new high blood pressure drug, developed by takeda, Japan, azisartan is a prodrug, which is hydrolyzed to azisartan during gastrointestinal absorption.On February 22, 2011, the FDA approved the potassium Azilsartan kamedoxomil tablets to treat primary hypertension.The Chinese patent issued CN1946717 is a compound patent applied in China for potassium azisartan ester, which will expire on February 22, 2025.

 

Specifications:
 

Item

Specification

Specific rotation

+39.5 to +41.5°

State of solution(transmittance)

Clear 98.0% min.

Chloride[cl]

0.020% max.

Ammonium [NH4]

0.02% max.

Sulfate[SO4]

0.020% max

Iron[Fe]

10ppm max.

Heavy metals [Pb]

10ppm max

Arsenic[As2O3]

1ppm max

Other amino acids

Chromatographically not detectable

Loss on drying

0.20% max.

Residue on ignition[sulfated]

0.10% max.

Assay

99.0% min

 
Application: 
 

Temple, sand selective blocking angiotensin Ⅱ and AT1 receptor (temple, sand for AT1 receptor affinity of AT2 receptors of more than 10000 times higher), thereby blocking angiotensin Ⅱ cause vasoconstriction, aldosterone secretion rising blood pressure effect.Its function is not dependent on the angiotensin Ⅱ synthesis way, so to avoid the effect of ACEI on slow excitation peptide level.Compared with angiotensin converting enzyme inhibitors (ACEI), both single and combined drugs have the advantages of stable blood pressure reduction, without causing dry cough, and stable and long-lasting effect on blood pressure reduction.It also has a potential protective effect on diabetics by partially activating the receptor gamma (ppar-gamma) by activating peroxidosomal proliferators, and clinical trials have shown that its clinical effect is better than that of the currently widely used drugs, such as olmezartan and valsartan.


Our strengths:
 
We can customize according to customer's requirement.
If you have any question pls mail us or call us.
 

 
 

Contact Details
Fedor

Phone Number : +86 18989305995

WhatsApp : +18989305995